Cochrane Abstracts
Immunotherapy for advanced or metastatic urothelial carcinoma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Immunotherapy for Advanced or Metastatic Urothelial Carcinoma." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440577/all/Immunotherapy_for_advanced_or_metastatic_urothelial_carcinoma.
Immunotherapy for advanced or metastatic urothelial carcinoma. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440577/all/Immunotherapy_for_advanced_or_metastatic_urothelial_carcinoma. Accessed March 24, 2025.
Immunotherapy for advanced or metastatic urothelial carcinoma. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440577/all/Immunotherapy_for_advanced_or_metastatic_urothelial_carcinoma
Immunotherapy for Advanced or Metastatic Urothelial Carcinoma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440577/all/Immunotherapy_for_advanced_or_metastatic_urothelial_carcinoma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immunotherapy for advanced or metastatic urothelial carcinoma
ID - 440577
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440577/all/Immunotherapy_for_advanced_or_metastatic_urothelial_carcinoma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
